SEC filing · 8-K

Summit Therapeutics Inc.: Material agreement

Summit Therapeutics agreed to sell convertible preferred stock to AstraZeneca for gross proceeds of $2.0 billion and collaborate on cancer clinical trials.

Filed September 29, 2026

Positive for the company

What happened

Summit Therapeutics entered into an agreement to sell 108,955.3686 shares of Class A Convertible Preferred Stock to AstraZeneca for $2.0 billion.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Summit Therapeutics Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.